Image may be NSFW.
Clik here to view.
Clik here to view.
OncoGenex’s OGX-427 drug gaining investor attention
Even though OncoGenex Pharmaceuticals (NASDAQ:OGXI) and its pivotal programs with lead oncology candidate, custirsen, are being closely followed, investors are beginning to notice the company’s second...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
OncoGenex Phase 3 prostate cancer trial fails
Top-line survival results of OncoGenex Pharmaceuticals’ (NASDAQ:OGXI) Phase 3 SYNERGY trial indicate that the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the...
View Article
More Pages to Explore .....
